clodronic acid Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
calcium metabolism regulator, pharmaceutical aid 690 10596-23-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • clodronic acid
  • clodronate
  • dichloromethylenediphosphonic acid
  • methanedichlorodiphosphonic acid
A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification.
  • Molecular weight: 244.88
  • Formula: CH4Cl2O6P2
  • CLOGP: -0.14
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 4
  • TPSA: 115.06
  • ALOGS: -1.52
  • ROTB: 2

Drug dosage:

DoseUnitRoute
1.60 g O
1.50 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.40 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 80 % Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability) 1 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.88 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.60 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.64 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 43.20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1986 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Osteonecrosis of jaw 83.23 42.19 22 241 34380 46651419

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event

Pharmacologic Action:

SourceCodeDescription
ATC M05BA02 MUSCULO-SKELETAL SYSTEM
DRUGS FOR TREATMENT OF BONE DISEASES
DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
Bisphosphonates
MeSH PA D050071 Bone Density Conservation Agents
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:50646 anti-osteoporotics

Drug Use (View source of the data)

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 0.13 acidic
pKa2 4.2 acidic
pKa3 5.18 acidic
pKa4 9.25 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Tyrosine-protein phosphatase non-receptor type 1 Enzyme WOMBAT-PK
ADP/ATP translocase 3 Enzyme WOMBAT-PK
ADP/ATP translocase 1 Transporter WOMBAT-PK
ADP/ATP translocase 2 Enzyme WOMBAT-PK

External reference:

IDSource
N0000166424 NUI
D03545 KEGG_DRUG
C0162357 UMLSCUI
CHEBI:59585 CHEBI
CHEMBL12318 ChEMBL_ID
DB00720 DRUGBANK_ID
D004002 MESH_DESCRIPTOR_UI
25419 PUBCHEM_CID
9605 IUPHAR_LIGAND_ID
4147 INN_ID
0813BZ6866 UNII
3350 RXNORM
003710 NDDF
387579006 SNOMEDCT_US
418080006 SNOMEDCT_US
768528000 SNOMEDCT_US

Pharmaceutical products:

None